

MANATEE: Roche and Genentech clinical study of GYM329 (RO7204239) in combination with risdiplam treatment in children with SMA



F Petridis¹, I Carruthers², H Kletzl³, C Martin², BB Zhang⁴, RS Scalco⁵

¹F. Hoffmann-La Roche Ltd, Basel, Switzerland; ²Roche Products Ltd, Welwyn Garden City, UK; ³Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; ⁴PD Neuroscience, Roche Products Ltd, Welwyn Garden City, UK; ⁵Pharma Development Neurology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

MANATEE (NCT05115110) is an international clinical trial aimed at understanding the safety and efficacy of GYM329 (RO7204239) in combination with risdiplam in children with SMA aged 2–10 years old.

1 Why is a combination of two treatments being assessed in the MANATEE study?

- Tremendous progress has led to the development and availability of three treatments approved by the U.S. Food and Drug Administration (FDA) that target the underlying cause of SMA.¹⁻³
- Additional therapies and approaches to treatment are needed to provide more treatment options for individuals with SMA. Assessing the potential benefit of combination treatment is an important step in SMA research and development.

2 Which treatments are being assessed in the MANATEE study?

Combining two treatments, which work differently in the body, could lead to more benefits for individuals with SMA.⁴



GYM329

- GYM329 is designed to inhibit myostatin, and potentially increase muscle size and growth.⁵



Risdiplam


- Risdiplam treats SMA by increasing and sustaining the production of survival of motor neuron (SMN) protein in the blood.⁶

The goal of GYM329 treatment, in combination with risdiplam, is to target the underlying cause of SMA by increasing SMN protein levels while also supporting muscle growth. This has the potential to further improve motor function and outcomes for people living with SMA.*

*The combination of GYM329 and risdiplam is an investigational (unapproved) drug combination that is being studied for the treatment of people with SMA. Efficacy and safety have not been established and this information is not a recommendation for use.

3 How is GYM329 designed to work?

- Based on animal studies, GYM329 (an investigational treatment) aims to block the function of myostatin. Myostatin is a naturally occurring protein that is produced by the body to prevent muscles from growing too large.⁵



4 Who can participate in the MANATEE Part 1 study?*



Aged 2–10 years at screening



Able to walk/run 10 meters in ≤30 seconds (ambulant)



Individuals need to be genetically diagnosed with SMA and show symptoms of the disease



Individuals who have not received treatments that block the function of myostatin




Individuals who have previously been treated with risdiplam (EVRYSDI®), nusinersen (SPINRAZA®) or onasemnogene abeparvovec (ZOLGENSMA®) are eligible, as well as those who have not received treatment before or are currently being treated with risdiplam†

*Estimated enrollment in Parts 1 and 2 = 180 participants. †Individuals must have discontinued nusinersen or onasemnogene abeparvovec treatment more than 90 days prior to enrollment.

5 How is the MANATEE study designed?

- MANATEE is a two-part study assessing the safety and efficacy of GYM329 (given once monthly by injection into the skin) in combination with risdiplam (a liquid given once daily by mouth or feeding tube) for the treatment of individuals with SMA:



*The treatment period is double-blind. In double-blind and randomized trials, participants are randomly assigned to receive placebo or treatment. Neither the doctor nor the participant are aware of who is receiving placebo and who is receiving treatment; this reduces bias in results. **After 24 weeks of treatment, the participant will receive GYM329 at the dose of their respective treatment cohort until the pivotal dose has been decided.

Study assessments



Motor function:

- Revised Hammersmith Scale
- 32-item Motor Function Measure
- Wearable device



Overall treatment properties:

- Treatment levels in the blood (pharmacokinetics)
- Effect of treatment on the body (pharmacodynamics)*



Muscle measures:

- Muscle strength (myometry)
- Muscle mass (dual-energy X-ray absorptiometry [DXA] scan, magnetic resonance imaging [MRI])†



Daily activities/independence:

- The SMA Independence Scale – ambulant module



Safety

*Including concentrations of the protein that GYM329 targets. †MRI will be conducted in Part 1 of the study only. Participants aged ≥5 years at screening.

6 Where are the MANATEE study sites located?

Approximately 15 trial sites have been selected for MANATEE Part 1.

The following countries are currently participating in this study:



References

1. ZOLGENSMA® FDA prescribing information: <https://www.fda.gov/media/126109/download> (Accessed June 2022);
2. SPINRAZA® FDA prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/209531b1.pdf (Accessed June 2022);
3. EVRYSDI® FDA prescribing information: https://www.gene.com/download/pdf/evrydsi_prescribing.pdf (Accessed June 2022);

4. Cure SMA Scientific Considerations for Drug Combinations. https://curesma.wpengine.com/wp-content/uploads/2020/03/03042020_Scientific-Considerations-for-Drug-Combinations_Final_Updated.pdf (Accessed June 2022);
5. Muramatsu H, et al. *Sci Rep.* 2021; 11:2160.
6. Poirier, et al. *Pharmacol Res Perspec.* 2018; 6:e00447.

Acknowledgments

We would like to thank the individuals and caregivers who have participated in our study program and Cure SMA for their ongoing partnership. The authors would also like to thank SMA Europe for their contributions. Editorial support was provided by Kathryn Russo, PhD, of Nucleus Global, funded by F. Hoffmann-La Roche Ltd. Genentech is a member of the Roche group.